{"groups":[{"description":"Participants receiving 50 mg of LDK378","id":"FG000","title":"LDK378 50 mg"},{"description":"Participants receiving 100 mg of LDK378","id":"FG001","title":"LDK378 100 mg"},{"description":"Participants receiving 200 mg of LDK378","id":"FG002","title":"LDK378 200 mg"},{"description":"Participants receiving 300 mg of LDK378","id":"FG003","title":"LDK378 300 mg"},{"description":"Participants receiving 400 mg of LDK378","id":"FG004","title":"LDK378 400 mg"},{"description":"Participants receiving 500 mg of LDK378","id":"FG005","title":"LDK378 500 mg"},{"description":"Participants receiving 600 mg of LDK378","id":"FG006","title":"LDK378 600 mg"},{"description":"Participants receiving 700 mg of LDK378","id":"FG007","title":"LDK378 700 mg"},{"description":"Participants receiving 750 mg of LDK378.","id":"FG008","title":"LDK378 750 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"28"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"12"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"139"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"36"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"39"}],"type":"Administrative problems"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"comment":"Started = Full Analysis Set and Safety Set","groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"255"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"9"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"246"}],"type":"Non-Small Cell Lung Cancer (NSCLC)"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"8"}],"type":"Dose-Determining Set (DDS)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"comment":"Small number of patients at 750 mg - non-NSCLC, assessment limited, not included in efficacy tables","groupId":"FG008","numSubjects":"9"}],"type":"Non-NSCLC"},{"achievements":[{"comment":"Completed - see explanation in Recruitment Details.","groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"14"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"255"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 304 patients were treated with LDK378 in the study, including 59 patients from the dose-escalation phase (including 10 patients at 750 mg) and 245 patients from the expansion phase treated at LDK378 750 mg.","recruitmentDetails":"Study was considered completed when all patients discontinued ceritinib treatment, \\& all required follow-up was completed or patient died, was lost to follow-up or withdrew their consent to further participate in study or last patient on treatment was enrolled to a separate protocol to continue receiving ceritinib treatment, whichever came first."}